Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the new world

Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the new world

Author Salay, Gerson Autor UNIFESP Google Scholar
Dorta, M. L. Autor UNIFESP Google Scholar
Santos, N. M. Autor UNIFESP Google Scholar
Mortara, Renato Arruda Autor UNIFESP Google Scholar
Brodskyn, C. Google Scholar
Oliveira, C. I. Google Scholar
Barbieri, C. L. Autor UNIFESP Google Scholar
Rodrigues, Mauricio M. Autor UNIFESP Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Fdn Oswaldo Crus
Univ Fed Gouania
Universidade Federal da Bahia (UFBA)
Abstract We evaluated whether four recombinant antigens previously used for vaccination against experimental infection with Leishmania (Leishmania) major could also induce protective immunity against a challenge with Leishmania (Viannia) braziliensis, the species responsible for 90% of the 28,712 annual cases of cutaneous and mucocutaneous leishmaniasis recorded in Brazil during the year of 2004. Initially, we isolated the homolog genes encoding four L. (V.) braziliensis antigens: (i) homologue of receptor for activated C kinase, (ii) thiol-specific antioxidant, (iii) Leishmania elongation and initiation factor, and (iv) L. (L.) major stress-inducible protein 1. At the deduced amino acid level, all four open reading frames had a high degree of identity with the previously described genes of L. (L.) major being expressed on promastigotes and amastigotes of L. (V.) braziliensis. These genes were inserted into the vector pcDNA3 or expressed as bacterial recombinant proteins. After immunization with recombinant plasmids or proteins, BALB/c mice generated specific antibody or cell-mediated immune responses (gamma interferon production). After an intradermal challenge with L. (V.) braziliensis infective promastigotes, no significant reduction on the lesions was detected. We conclude that the protective immunity afforded by these four vaccine candidates against experimental cutaneous leishmaniasis caused by L. (L.) major could not be reproduced against a challenge with L. (V.) braziliensis. Although negative, we consider our results important since they suggest that studies aimed at the development of an effective vaccine against L. (V.) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World, should be redirected toward distinct antigens or different vaccination strategies.
Language English
Date 2007-09-01
Published in Clinical and Vaccine Immunology. Washington: Amer Soc Microbiology, v. 14, n. 9, p. 1173-1181, 2007.
ISSN 1556-6811 (Sherpa/Romeo, impact factor)
Publisher Amer Soc Microbiology
Extent 1173-1181
Origin http://dx.doi.org/10.1128/CVI.00060-07
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000249488400015
URI http://repositorio.unifesp.br/handle/11600/29987

Show full item record




File

Name: WOS000249488400015.pdf
Size: 613.3Kb
Format: PDF
Description:
Open file

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account